A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients

• Autori principali: Dunbar Ivy, MD (Autore), Maurice Beghetti, MD (Autore), Ernesto Juaneda-Simian, MD, PhD (Autore), Diane Miller, PhD (Autore), Mary Ann Lukas, MD (Autore), Chris Ioannou, PhD (Autore), Malek Okour, PhD (Autore), Jun Narita, MD (Autore), Rolf M.F. Berger, MD, PhD (Autore)
• Natura: Libro
• Pubblicazione: Elsevier, 2020-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Objective: To assess the safety and efficacy of the endothelin receptor antagonist ambrisentan in pediatric pulmonary arterial hypertension (PAH). Study design: In this open-label, phase IIb study, patients with PAH aged 8 to <18 years were randomized to low- or high-dose ambrisentan for 24 weeks...